SonoThera Launches $125M Series B at 44th J.P. Morgan Healthcare Conference to Advance Multiple Genetic Medicine Programs Toward First-in-Human Studies

SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation ...
TMCnet

Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts

LYNX-3, the second pivotal Phase 3 trial in keratorefractive participants with visual disturbances under mesopic, low-contrast conditions, is ongoing with topline results expected in the first half of ...
Le Lézard

ENYO Pharma Announces Completion and Topline Data From Phase 2 Alpestria-1 Clinical Study in Alport Syndrome Demonstrating Vonafexor Reverses Kidney Function Decline and Has ...

ENYO Pharma ("ENYO"), a clinical-stage biopharmaceutical company developing innovative therapies for kidney diseases, today confirmed positive results from its Phase 2 Alpestria-1 study of vonafexor ...